全文获取类型
收费全文 | 267933篇 |
免费 | 34050篇 |
国内免费 | 10762篇 |
专业分类
耳鼻咽喉 | 1847篇 |
儿科学 | 3557篇 |
妇产科学 | 5524篇 |
基础医学 | 19851篇 |
口腔科学 | 2570篇 |
临床医学 | 22051篇 |
内科学 | 38023篇 |
皮肤病学 | 1619篇 |
神经病学 | 1986篇 |
特种医学 | 8452篇 |
外国民族医学 | 262篇 |
外科学 | 36758篇 |
综合类 | 37075篇 |
现状与发展 | 57篇 |
一般理论 | 3篇 |
预防医学 | 14117篇 |
眼科学 | 437篇 |
药学 | 20628篇 |
165篇 | |
中国医学 | 9259篇 |
肿瘤学 | 88504篇 |
出版年
2024年 | 854篇 |
2023年 | 5732篇 |
2022年 | 11068篇 |
2021年 | 14069篇 |
2020年 | 13241篇 |
2019年 | 11796篇 |
2018年 | 11409篇 |
2017年 | 11898篇 |
2016年 | 13037篇 |
2015年 | 14492篇 |
2014年 | 21362篇 |
2013年 | 21062篇 |
2012年 | 17098篇 |
2011年 | 17802篇 |
2010年 | 13109篇 |
2009年 | 13199篇 |
2008年 | 13453篇 |
2007年 | 12707篇 |
2006年 | 11533篇 |
2005年 | 9322篇 |
2004年 | 7708篇 |
2003年 | 6424篇 |
2002年 | 5494篇 |
2001年 | 5015篇 |
2000年 | 4215篇 |
1999年 | 3556篇 |
1998年 | 3057篇 |
1997年 | 2693篇 |
1996年 | 2276篇 |
1995年 | 2051篇 |
1994年 | 1763篇 |
1993年 | 1396篇 |
1992年 | 1240篇 |
1991年 | 1107篇 |
1990年 | 872篇 |
1989年 | 788篇 |
1988年 | 687篇 |
1987年 | 569篇 |
1986年 | 462篇 |
1985年 | 576篇 |
1984年 | 475篇 |
1983年 | 306篇 |
1982年 | 352篇 |
1981年 | 291篇 |
1980年 | 275篇 |
1979年 | 208篇 |
1978年 | 167篇 |
1977年 | 130篇 |
1976年 | 140篇 |
1975年 | 67篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
《Saudi Pharmaceutical Journal》2022,30(11):1572-1588
Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of a metabolic syndrome caused by excessive accumulation of fat in the liver. Orthosiphon stamineus also known as Orthosiphon aristatus is a medicinal plant with possible potential beneficial effects on various metabolic disorders. This study aims to investigate the in vitro inhibitory effects of O. stamineus on hepatic fat accumulation and to further use the computational systems pharmacology approach to identify the pharmacokinetic properties of the bioactive compounds of O. stamineus and to predict their molecular mechanisms against NAFLD. Methods: The effects of an ethanolic extract of O. stamineus leaves on cytotoxicity, fat accumulation and antioxidant activity were assessed using HepG2 cells. The bioactive compounds of O. stamineus were identified using LC/MS and two bioinformatics databases, namely the Traditional Chinese Medicine Integrated Database (TCMID) and the Bioinformatics Analysis Tool for the Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM). Pathway enrichment analysis was performed on the predicted targets of the bioactive compounds to provide a systematic overview of the molecular mechanism of action, while molecular docking was used to validate the predicted targets. Results: A total of 27 bioactive compounds corresponding to 50 potential NAFLD-related targets were identified. O. stamineus exerts its anti-NAFLD effects by modulating a variety of cellular processes, including oxidative stress, mitochondrial β-oxidation, inflammatory signalling pathways, insulin signalling, and fatty acid homeostasis pathways. O. stamineus is significantly targeting many oxidative stress regulators, including JNK, mammalian target of rapamycin (mTOR), NFKB1, PPAR, and AKT1. Molecular docking analysis confirmed the expected high affinity for the potential targets, while the in vitro assay indicates the ability of O. stamineus to inhibit hepatic fat accumulation. Conclusion: Using the computational systems pharmacology approach, the potentially beneficial effect of O. stamineus in NAFLD was indicated through the combination of multiple compounds, multiple targets, and multicellular components. 相似文献
3.
4.
《Cancer cell》2022,40(3):318-334.e9
- Download : Download high-res image (268KB)
- Download : Download full-size image
5.
6.
7.
8.
9.
目的探究老年胃癌患者术前血清白细胞介素6 (IL-6)、胃蛋白酶原(PG)Ⅰ、Ⅱ及PG-Ⅰ/Ⅱ比值在患者预后评估中的意义。方法选择2016年1月—2017年1月南通大学附属海安医院收治的101例外科手术治疗的老年胃癌患者为研究对象。收集患者的临床病理资料,检测血清IL-6和PG-Ⅰ/Ⅱ水平。以全因死亡为随访终点,使用Kaplan-Meier曲线明确患者预后与各指标间的关系。结果受试者工作特征曲线提示,IL-6、PG-Ⅰ和PG-Ⅰ/Ⅱ比值在最佳切割值为10.23pg/mL、30.65μg/L和2.44时,可评估患者的预后,而PG-Ⅱ则无法评估患者的预后。与IL-6≤10.23pg/mL组相比,IL-6> 10.23pg/mL组的肿瘤细胞分化更差、TNM分期Ⅲ期比例明显升高。Kaplan-Meier曲线结果表明,IL-6> 10.23pg/mL组的中位生存期显著短于IL-6≤10.23pg/mL组(28个月vs47个月,P<0.001);PG-Ⅰ≤30.65μg/L组的中位生存期显著短于PG-Ⅰ>30.65μg/L组(34个月vs49个月,P=0.008);PG-Ⅰ/Ⅱ≤2.44组的中位生存期显著短于PG-Ⅰ/Ⅱ> 2.44组(29个月vs56个月,P=0.02)。多因素Cox回归分析表明,肿瘤分化程度、TNM分期、IL-6及PG-Ⅰ/Ⅱ比值是影响患者生存率的独立危险因素。结论术前检测IL-6及PG-Ⅰ/Ⅱ比值有助于评估老年胃癌患者的预后。 相似文献
10.